Establishment and Histopathological Characterization of a KYSE-30 Subcutaneous Xenograft Model of Esophageal Squamous Cell Carcinoma

Background/Objectives: Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis and limited treatment options, highlighting the need for reliable preclinical models for translational research. Although xenograft models are widely used in cancer biology, systematic characterization of subcutaneous ESCC models under defined implantation conditions remains limited. The objective of this study was to systematically compare implantation conditions and define histopathological and growth-related parameters that enable reproducible tumor establishment while maintaining a practical experimental window for therapeutic studies. Methods: We established and characterized a subcutaneous ESCC xenograft model using human ESCC cell line KYSE-30 implanted into immunodeficient J:NU mice. Tumor growth dynamics were compared under three implantation conditions: cells suspended in phosphate-buffered saline (PBS), Matrigel (Corning, basement membrane matrix), or Matrigel diluted with PBS. Results: Tumors generated from Matrigel-embedded cells exhibited rapid growth, reaching substantial size within approximately one week after implantation, which limited their utility for controlled therapeutic studies. In contrast, tumors generated from cells suspended in Matrigel + PBS demonstrated slower but consistent expansion, providing a more suitable and reproducible experimental window for therapeutic intervention. Cells injected in PBS alone showed inefficient tumor establishment. Histopathologic and immunohistochemical analyses revealed matrix-dependent differences in necrosis, stromal organization, and proliferative activity, while confirming epithelial tumor identity and baseline vascularization. Conclusions: Collectively, these findings define a reproducible KYSE-30 subcutaneous xenograft model and identify Matrigel dilution with PBS as an optimal implantation strategy that balances reliable tumor engraftment with controlled tumor growth suitable for therapeutic studies.